Injected drug can help fight against osteoporosis in women

Primary tabs

Injected drug can help fight against osteoporosis in women

According to latest finding, abaloparatide appears to reduce bone fractures better than the current drug Forteo and placebo in postmenopausal women with osteoporosis.. This investigational drug abaloparatide-subcutaneous (SC) increase bone mineral density in postmenopausal women with osteoporosis and reduce their risk of vertebral and nonvertebral fractures.

In phase III trial, researchers found that vertebral fractures occurred less frequently in the two treatment groups than in the placebo group. The researchers notified that patients who received abaloparatide treatment had fewer 0.58% spine fractures during the study period vs 0.84% in the teriparatide (Forteo) group and 4.22% in the placebo group. Similarly, upon comparison of abaloparatide the incidence rate for non-vertebral fracture was lower (2.7%) for abaloparatide group whereas it was slightly higher (3.3%) in the teroparatide group, with the highest (4.7%) being in placebo group.

Based on 2010 U.S. Census data, a study estimated the prevalence of osteoporosis among women 50 to 69 years of age in 3 million population. Over the course of 18 months, researchers administered injections of abaloparatide, teriparatide, or placebo to nearly 2500 female participants with an average age of 69. Around 2000 of them completed the study, bone mineral density is more with abaloparatide than placebo and this study was recently published in JAMA.     

Additionally, hypercalcemia (abnormally high levels of calcium in the blood) was observed in 3% fewer of those on the abaloparatide treatment than on teriparatide (6%). There was no difference among the groups in other serious side effects, such as nausea and heart palpations.

An editorial accompanying the study said which drug is selected may be less important than identifying and starting an approved treatment. "The bar is high for any preventive treatment -- in the efforts to prevent a fracture that may or may not ever occur, prescribers do not want to prescribe a therapy that causes a new problem. The way forward for fracture prevention involves not only the development of better therapies and easier delivery systems, but also improved adoption of existing osteoporosis therapies for patients with prior fractures and minimization of adverse effects, particularly those associated with long-term use," the editorial said.


Journal of the American Medical Association

Link to the source:

Original title of article:

Injected Drug May Help Fight Osteoporosis in Women


Dr. Paul Miller

Journal of the American Medical Association
Therapeutic, Abaloparatide, Teriparatide, Osteoporosis, Bones, Parathyroid Hormone, Phase 3 Trial, Efficacy, Safety, Hypercalcemia, Nausea, Heart palpations, Parenteral
Log in or register to post comments